Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Terns Pharmaceuticals Inc TERN

Healthcare Biotechnology
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its pipeline includes three clinical-stage development programs: TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:TERN)

Terns Pharmaceuticals Announces Positive Early Data from Phase 1 CARDINAL Trial of TERN-701 for Chronic Myeloid Leukemia

GlobeNewswire December 3, 2024

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

GlobeNewswire December 2, 2024

Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors

GlobeNewswire November 18, 2024

Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates

GlobeNewswire November 12, 2024

Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences

GlobeNewswire November 6, 2024

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

GlobeNewswire October 7, 2024

Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire September 12, 2024

Terns Announces Pricing of Upsized $150.15 Million Public Offering

GlobeNewswire September 10, 2024

Terns Announces Proposed Public Offering

GlobeNewswire September 9, 2024
View More News ››

Opinion & Analysis (NDAQ:TERN)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:TERN)

Buy Recommendation Issued On TERN By Deutsche Bank

Breaking News: $TERN Buy Recommendation Issued On TERN By Deutsche Bank2024-09-10 10:15:04 ET Deutsche Bank analyst issues BUY...
whytestocks - September 10, 2024

Buy Recommendation Issued On TERN By Loop Capital Markets

Breaking News: $TERN Buy Recommendation Issued On TERN By Loop Capital Markets2024-09-10 10:15:04 ET Loop Capital Markets analyst issues...
whytestocks - September 10, 2024

TERN Breaking 10$ on the News

TERN Breaking 10$ on the News
10QKing - September 9, 2024

Terns Pharmaceuticals: A Promising Pipeline Targeting Seriou

http://beyondspx.com/2024/08/02/terns-pharmaceuticals-a-promising-pipeline-targeting-serious-diseases/
MikeTester - August 3, 2024
View more Bullboard ››

K9 Gold Corp

K9 Gold Corp

K9 Gold Corp. is engaged in the business of identification, acquisition and exploration of mineral interests. The Company’s ...
View More »